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Abstract 
Background: Hepatitis, a highly contagious viral infection, is one of the leading killer diseases globally caused by 
hepatitis virus. Among the existing viral causes for hepatic failure, hepatitis B virus (HBV) plays a significant role with 
devastating implications, especially when combined with other viral infections such as human immunodeficiency 
virus (HIV). Co-infection with hepatitis B virus and HIV leads to increased morbidity and mortality as compared to 
independent HIV and HBV infections. In this study, we aimed to assess the seroprevalence of HBV and HIV coinfection 
and associated risk factors among pregnant women in a selected hospital facility around Addis Ababa, Ethiopia.
Methods: A total of 215 pregnant women were recruited between July and October 2014 from Tirunesh Beijing 
General Hospital. A pretested and structured questionnaire was used to collect socio-demographic characteristics and 
possible risk factors. In addition, 5 ml venous blood was collected and centrifuged to estimate the seroprevalence of 
HBV and HIV. Descriptive statistics and logistic regression analysis were done and a P value less than 0.05 was consid-
ered statistically significant.
Results: The overall prevalence of hepatitis B virus infection was 13 (6 %). This positivity was different across different 
age categories: 1 (11.1 %), 3 (4.5 %), 6 (6 %), 1 (3.2 %), and 2 (25 %) among those between 15–19, 20–24, 25–29, 30–34, 
and 35–39 years, respectively. However, a statistically significant association was not established between age and 
HBV. Among the total, 9 (4.2 %) of the positive cases were detected among primary school completed. Multivariate 
analyses indicated that history of abortion (p = 0.003), history of surgery (p = 0.0.022), and tattooing (p = 0.033) were 
significantly associated with HBV infection. A total of 9 (4.2 %) women were found to be HIV seropositive, of whom 2 
(22.2 %) were co-infected with HBV.
Conclusions: We observed a relatively higher seroprevalence of HBV infection among pregnant women in the study 
area, in which majority of the cases had underlying risk factors for acquiring the infection. Since none of the mothers 
were vaccinated for HBV, the possibility of perinatal transmission is inevitable. Hence, routine screening and immuni-
zation against HBV during pregnancy and health education are highly warranted to alleviate the situation.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
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Background
Hepatitis B virus (HBV)-associated infection is one of 
the leading causes of liver diseases causing serious public 
health problem worldwide. Since the majority of infected 
individuals remain as asymptomatic carriers, most 
infected individuals die of the infection without notice 
and hence called as a “silent killer” [1].
The prevalence of chronic HBV infection varies greatly 
in different part of the world. According to World Health 
Organization (WHO) classification, the world-wide prev-
alence of chronic HBV infection can range from high 
(above 8  % as in most resource-limited settings) to low 
(below 2 % as in most developed settings) [2].
Viral hepatitis is a leading cause of maternal complica-
tion and vertical transmission that cause fetal and neo-
natal hepatitis which can have serious effects on the 
neonate, leading to impaired mental and physical health 
later in life [3]. A leading cause of maternal mortal-
ity is also said to be the most familiar cause of jaundice 
in pregnancy [4]. Perinatal transmission of HBV often 
occurs when the mother presents with acute infection 
during late pregnancy, in the first postpartum or if the 
mother is a chronic HBsAg carrier [5].
Hepatitis B virus (HBV) and Human immunodeficiency 
virus (HIV) infections are posing huge health impact 
throughout the world and the problem is higher in devel-
oping countries, very particularly, in Africa. The two 
most significant viruses share similar ways of transmis-
sion in humans, which accounts for the high frequency of 
HIV-HBV co-infections [6].
Co-infection with hepatitis B virus and HIV leads to 
increased morbidity and mortality as compared to inde-
pendent HIV and HBV infections. In areas where HBV 
infection is either endemic or intermediate to high, the 
prevalence rate of HIV/HBV co-infection is recorded 
as high as 10–20  %. The prevalence rate can be as high 
as 20–25  % in countries where the viruses are highly 
endemic [7–9]. The two most significant infectious 
agents are transmitted by sexual intercourse and positive 
mothers to fetus or newborns. Studies conducted in Ethi-
opia have revealed that HBV and HIV are endemic with 
regional variation [10–12].
In Ethiopia as part of other sub-saharan Africa coun-
tries, the prevalence of HIV and liver disease is high 
and posing a great public health problem. Apart from 
its significant prevalence, liver disease contributes 
approximately 12 % of the hospital admissions and 31 % 
of the mortality in medical wards of Ethiopian Hospi-
tals [13].
The dual burden of HBV and HIV infection in Ethiopia 
was revealed by many seroepidemiological researches con-
ducted in different segments of the country with regional 
variation. In a study from a rural hospital in Southern Ethi-
opia, the seroprevalence was 6.1 % for HBV and 1.8 % for 
HIV. Co-infection with HIV-1 and HBV was detected in 
one patient (prevalence: 0.6 %) [14]. According to a hospi-
tal-based cross-sectional study conducted in Felege Hiwot 
Referral Hospital, northwest Ethiopia, the seroprevalence 
of hepatitis B infections was found to be 4.4 % [15].
A cross-sectional study which was conducted in Addis 
Ababa to investigate seroprevalence and transmission of 
Hepatitis B virus among delivering women revealed that 
8/265 (3.0  %) of mothers were positive for Hepatitis B 
Virus surface antigen [16].
Another study from Bahir Dar which has included a 
total of 318 pregnant women was carried out to deter-
mine seroprevalence and risk factors of hepatitis B virus 
and human immunodeficiency virus infection among 
pregnant women. Overall, 21/318 (6.6  %) and 12/318 
(3.8 %) of the pregnant women were positive for HIV and 
HBsAg, respectively. Of these, HIV/HBV co-infection 
rate was 4 (19.0 %) [17].
As part of reducing maternal and child mortality to 
achieve one of the millennium development goals (MDGs) 
[18], Ethiopia rolled out childhood immunization against 
HBV in 2007. The vaccine is delivered in a pentavalent 
form as part of expanded program on immunization (EPI) 
of newborns. Despite this effort, newborns are vaccinated 
without a prior screening of mothers for underlying hepa-
titis infection. This study aims to assess the current esti-
mate of HBV infection among pregnant mothers attending 
one of the antenatal care facilities around Addis Ababa and 
investigate possible factors for HBV infection.
Results
General characteristics
The study included a total of two hundred fifteen preg-
nant women. Table 1 indicates general characteristics of 
ANC attendant. The median age of ANC attendant was 
26 ± 3.94 years. Of the total, 211 (98.1 %) were married 
who were found to be in monogamous relationship and 
majority, 164 (76.3 %) were orthodox religion followers. 
84 (39.1  %) attended primary school and majority, 129 
(60 %), were house wives.
HBV prevalence and analyses of risk factors
The overall seroprevalence for HBsAg among the study 
population was about 6 % (13/215). There was an overall 
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trend of higher seropositivity for HBV infection among 
older age groups (between 35 and 39  years) 2 (25  %) 
compared to the other age groups: 11.1  % among (15–
19  years), 4.5  % among (20–24  years), 6  % among (25–
29  years), and 3.2  % among (30–34  years). The level of 
literacy in the majority of the positive cases was low; 8 
(9.5 %) were from a primary school level. Of the total, 9 
(4.19  %) participants were HIV positive and prevalence 
of HIV/HBV co-infection was 22.2 % (two HBV positive 
cases out of nine HIV positive cases).
A multivariate analysis of different variables indicated 
that those having a history of abortion had a 19 times 
more chance of positivity for HBsAg than those with-
out [AOR = 19 (CI 2.78–130.367); p = 0.003]. Similarly, 
those with a history of previous surgery had a 9.8 times 
more chance of positivity for HBsAg compared to their 
counterparts [AOR = 9.8 (CI 1.392–69.610); p = 0.022]. 
Moreover, the odds of having HBsAg positivity was 7.7 
times more likely among those who were with experience 
of tattoo [OR = 7.7 (CI 1.185–50.28); p = 0.033]. Except 
abortion, surgery, and tattoo, other risk factors included 
in the study had not showed statistically significant asso-
ciation (p > 0.05) with the HBsAg positivity. HBV prev-
alence and association with risk factors are shown in 
Table 2.
Discussion
The present study will contribute to the understanding 
of the current burden of HBV among pregnant moth-
ers attending antenatal clinics. In addition, it will sig-
nificantly contribute to providing insights to the current 
practice of HBV vaccination in newborns in Ethiopia 
as newborns are given the vaccine without screening. 
Therefore, the findings of this study will provide insights 
for policy makers to implement the routine practice of 
screening and immunization of pregnant mothers during 
their antenatal visits.
Screening apparently healthy pregnant women does 
have a paramount importance from the perspective of 
particular disease investigation, diagnosis, and imple-
mentation evidence-bases medical intervention for 
chronic HBV infection. Especially, this should be given 
due emphasis in pregnant women so as to prevent the 
transmission of HBV to their new born [19].
In agreement with World Health Organization (WHO) 
grouping, the prevalence of HBV (6 %) was intermediate 
(2–7 %) [20]. The finding was higher than research report 
from Jimma (3.7  %), Addis Ababa (3  %), and Bahir Dar 
(3.8  %), Ethiopia [10, 16, 17]. In comparison with other 
countries, it was turned out to be higher than a study 
from Turkey (2.8  %) [21], India (0.9  %) [22], and Libya 
(1.5 %) [23]. In contrast, it was lower than the study doc-
umented in Taiwan (15.5 %) [24] and Gondar in Ethiopia 
(7.3  %) [12]. These differences might be attributable to 
socio-demographic characteristics, cultural and behav-
ioral differences for the risk factors of HBV infection, 
methodological difference, and the obvious natural dif-
ference linked with various geographical situations.
HBsAg sero-status was comparable with research 
reports from Debre Tabor (North West) (5.3  %) [25] 
and Niger (5.6 %) [26]. The explanation for this could be 
because we have engaged the same risk groups. In addi-
tion, this similarity would be justified by the test method 
principle similarity employed to investigate HBsAg.
According to previous epidemiological studies, there 
has been a link between age and the acquisition of HBsAg 
that indicates, the age of acquiring the infection as one 
of the major determinant factors for HBsAg positivity 
[27]. In our study, higher prevalence was observed in the 
age groups greater than 25 years in agreement with study 
from Addis Ababa Ethiopia (p  >  0.05) [14] and China 
Table 1 Socio-demographic characteristics distribution 
among  pregnant women attending Tirunesh Beijing Hos-
pital, 2014, Addis Ababa, Ethiopia
Socio-demographic Frequency
Variables Number (n) Percent (%)
Residence
 Urban 205 95.3
 Rural 10 4.7
Age (median = 26 years)
 15–19 9 4.2
 20–24 67 31.2
 25–29 100 46.5
 30–34 31 14.4
 35–39 8 3.7
Stage of pregnancy
 First trimester 10 4.7
 Second trimester 17 7.9
 Third trimester 188 87.4
Educational status
 Illiterate 40 18.6
 Primary school 84 39.1
 Secondary school 55 25.6
 Certificate and diploma 24 11.2
 Degree and above 12 5.6
Occupational status
 House wife 129 60
 Government organization 19 8.8
 Private organization 41 19.1
 Merchant 9 4.2
 Farmer 9 4.2
 Student 3 1.4
 Others 5 2.3
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(p = 0.001) [28]. Furthermore, a study from Saudi Arabia 
showed that HBV prevalence is higher among age greater 
than 25 years compared to those less than 25 years [29].
In Ethiopia, the overall adult HIV prevalence has 
remained low. The prevalence among adults of age 15–49 
in the 2011 EDHS was 1.5 percent. Among regions, HIV 
prevalence was highest in Gambela (6.5 percent) and in 
Addis Ababa (5.2 percent) [30]. In this study, the overall 
HIV prevalence was 4.2 % which was lower than research 
report from Bahir Dar and Gondar, Ethiopia, respectively 
[12, 17]. HIV prevalence was higher than the study con-
ducted in rural hospital in Southern Ethiopia (1.8 %) [14] 
and Mali (0.4 %) [31].
Age-wise HIV prevalence revealed that majority of 
HIV positive cases were distributed within age group of 
25–29  years. In contrary, study from Gonder, Ethiopia 
[12] and Nigeria (8.4 %) [20] reported higher HIV preva-
lence in the age group of 21–24 years. But as a matter of 
fact, aforementioned age categories are highly subjected 
age group for HIV and sexually transmitted infection 
which share the same transmission mode like HBV, HCV, 
and the likes. The most probable explanation could be 
related with sexual or other risky health behaviors.
The prevalence of HIV/HBV co-infection, accounting 
2 (22.2  %), was higher than the study done in Southern 
Ethiopia (0.6 %) [14] and Nigeria (9.5 %) [20]. In contrast, 
current HIV/HBV co-infection was comparable with a 
study conducted in Bahir Dar, Ethiopia (19 %) [17]. Most 
of the time, appearance of HBV and HIV infection is 
common among risk groups, because both HBV and HIV 
share common mode of transmission.
In multi-variate analysis, pregnant women with history 
of abortion were about 19 times more likely to be positive 
for HBsAg (AOR = 19; CI = 2.78–130.367); (p = 0.003). 
This variable was significantly associated with HBsAg 
positivity [32]. Study participants who have had body tat-
tooing on any part of their body was also 7.7 times more 
likely to be HBsAg positive (AOR = 7.7; CI 1.185–50.28; 
p  =  0.033) than their counterparts. Our finding was 
supported by studies conducted in Mali [33] and Addis 
Ababa [11], Ethiopia which reported that body tattoo-
ing on any part shown to be significant predictor of HBV 
prevalence. Moreover, undergoing surgical procedure 
was significantly associated with and important predic-
tors of hepatitis B infection (AOR  =  9.8; CI  =  1.392–
69.610; p = 0.022) [34].
The sero-markers that we have used to detect HBV 
infection were only HBSAg and it was not possible 
to investigate the transmission rate. Earlier studies in 
Ethiopia, on the other hand, showed a minimal risk of 
Table 2 HBsAg status and association with potential risk factors among pregnant women at Tirunesh Beijing Hospital, 
2014 (n = 215)
Risk factors HBsAg result
Positive Negative COR (CI) AOR (CI) P value
Abortion
 Yes 10 35 15.905 (4.162–60.78) 19 (2.78–130.367) 0.003
 No 3 167 Ref. –
Blood donation
 Yes 5 2 62.5 (10.481–372.702) 20.76 (0.761–566.8) 0.072
 No 8 200 Ref. –
History of hospitalization
 Yes 8 27 10.370 (3.159–34.040) 0.772 (0.072–8.298) 0.831
 No 5 175 Ref. –
Surgery
 Yes 11 28 34.179 (7.192–162.422) 9.84 (1.392–69.610) 0.022
 No 2 174 Ref. –
History of injection
 Yes 12 166 2.6 (0.328–20.656) 1.10 (0.087–14.026) 0.939
 No 1 36 Ref. –
Tattooing
 Yes 9 44 8.08 (2.375–27.482) 7.720 (1.185–50.28) 0.033
 No 4 158 Ref. –
HIV status
 Yes 2 7 5.065 (0.939–27.306) 8.201 (0.346–194.423) 0.193
 No 11 195 Ref. –
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perinatal transmission of HBV [35]. However, researches 
conducted elsewhere estimated that transmission rates 
can be as high as 12, 25, and 70–90  %, respectively, in 
HBeAg-negative/anti-HBe-positive mothers, HBeAg-
negative/anti-HBe-negative mothers, and HBeAg-posi-
tive/anti-HBe-negative mothers [36].
According to research findings, a perinatal transmis-
sion was found to be associated with HBeAg positivity 
and viral load. It was noted that the risk of transmission 
was significantly higher from HBeAg-positive moth-
ers compared with HBeAg-negative mothers, and from 
mothers with a very high viral load compared with moth-
ers with high or low viral loads. Perinatal transmission 
was not seen in babies born to mothers with HBV DNA 
levels <108 copies/mL or mothers who were negative for 
HBeAg [37].
By considering that intrauterine transmission is the 
major way of HBV transmission from positive mothers to 
their fetus/newborn, particularly in HBV endemic coun-
tries, all pregnant women should be screened for hepati-
tis B virus and those found to be positive need to be given 
HBIG prophylaxis [14]. Immunizing newborns with 
the hepatitis B vaccine should be the highest priority in 
highly endemic areas where the contribution of perina-
tal transmission to the overall disease burden is greatest. 
However, even in countries with a relatively low preva-
lence of chronic HBV infection, implementation of a 
birth dose of hepatitis B results in an additional 10–20 % 
reduction in HBV mortality [38, 39].
Taking into account the impact of viral hepatitis due 
to the leading route of mother-to-child transmission, 
designing and implementing intervention strategies 
to reduce the vertical transmission of HBV and HCV 
have paramount importance. Administration of at-birth 
prophylaxis of newborns of HBV-infected mothers with 
specific immunoglobulin and vaccine plus administration 
of antivirals (tenofovir or telbivudine) in the third tri-
mester of pregnancy (in case of high maternal viral load) 
greatly reduce the risk of transmission [40].
While treating, continuing, and stopping HBV therapy, 
all decisions required about the risks and benefits for 
both the mother and fetus. In addition, the trimester of 
the pregnancy and the stage of the mother’s liver disease 
are important factors. Treatment in the third trimester 
may be considered to aid in the prevention of perinatal 
transmission, which appears to be most pronounced in 
mothers with high viral loads [41].
Maternal-infantile transmission is a major way of 
transmission route for HBV and HIV; strategies targeted 
at disrupting this pathway would greatly diminish the 
number of new infections and would mitigate the suffer-
ing imposed by the disease on the individuals, families, 
society and the country at large society. As a result, we 
recommend that studies conducted in the future need to 
consider HBeAg seromarker in order to detect intrauter-
ine transmission rate.
Prevention of HBV infection, which can be done 
through vaccination, is a crucial measure so as to mini-
mize the world-wide occurrence of HBV infection. Vac-
cine-mediated intervention is preferred over the other 
way of healthcare interventions for its being economi-
cally advantageous. As per the year 1991 WHO recom-
mendation, all countries were urged to introduce a health 
policy of universal hepatitis B vaccination to prevent and 
control HBV infection and its long-term sequelae on a 
global scale [42, 43].
In Ethiopia, EPI was launched at nation-wide scale in 
1980 with the aim of providing immunization services 
to all children under the age of 2 years [44]. In the light 
of the WHO recommendations and the epidemiologi-
cal and medical picture, Ethiopia is a candidate for the 
introduction of HBV vaccination as part of the National 
EPI program. Despite a number of studies conducted to 
assess the impact of HBV infection, Ethiopia rolled out 
infant immunization against hepatitis in 2007. Currently, 
the vaccine is provided as part of expanded program 
on immunization (EPI), despite no routine screening of 
expecting mothers.
The prevalence of HBV infection in the pregnant 
women, though lower than other reports conducted else-
where, is still important. For the purpose of the study, 
only HBsAg was determined which tells about active 
infection rather than total infection rate. In contrary, 
investigation of seromarkers including anit-HBC and 
HBC antigen would have great potential to trace the 
overall distribution of HBV infection and indicators of 
the total infection rate in a certain population. These can 
be considered as the major limitation of this study. More-
over, unfortunately, it was difficult to follow-up these 
women till delivery to establish vertical transmission and 
its associated factors.
Conclusions
The present study showed an intermediate prevalence 
of HBV infection among pregnant women according to 
World Health Organization’s classification. A 6 % overall 
prevalence of HBV infection in our study setting among 
pregnant mothers attending antenatal care facility indi-
cates the need for timely intervention strategies to allevi-
ate the burden of HBV infection in the nearby community.
Although earlier studies indicated a minimal role for 
perinatal and vertical transmission of HBV infection, the 
impact of health education cannot be neglected, particu-
larly with the observed risk factors such as body tattoo-
ing, abortion, and previous history of surgery as a direct 
inflict of existing health facilities.
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Furthermore, the observed prevalence might also war-
rant the introduction of routine screening of hepatitis in 
all pregnant women and those in the reproductive age 
group by large. This would particularly be important, 
considering the current practices of infant immuniza-
tion with HBV that is provided without prior screening 
of expecting mothers. However, since there is no treat-
ment guidelines neither confirmatory tests available in 
most health facilities in Ethiopia at the moment, a wider 
scale study with a larger cohort of population in different 
health facilities is warranted.
Methods
Study setting and population
This cross-sectional study was conducted in one of the 
general hospitals, Tirunesh Beijing Hospital, located at 
the periphery of Addis Ababa, Ethiopia, between July 
and October 2014. A total of 215 pregnant women whose 
age was greater than 18 years, attending antenatal clinic 
(ANC) at the Tirunesh Beijing Hospital, were recruited 
consecutively. All socio-demographic information were 
collected from all participants using a standard question-
naire that was pretested. All participants gave written 
informed consent before enrollment to the study and test 
results were communicated for proper management and 
care of the study participants.
Sample collection and detection of antibody for Hepatitis 
surface antigen (HBsAg)
Five ml of venous blood was collected aseptically and 
centrifuged to separate the serum. Serum samples were 
then stored at −20 °C until assayed for antibodies against 
hepatitis surface antigen (HBsAg) using one-step HBsAg 
test strip (Linear Chemicals, Joaquim Costa, Barcelona, 
Spain). In addition to HBsAg, samples were screened for 
HIV antibody using commercially available rapid test kits 
in accordance with the national HIV test algorithm. To 
check for the reliability of the tests, we strictly followed 
the manufacturers’ instructions; both positive and nega-
tive controls were run alongside of the tests.
Statistical analysis
Data were checked for completeness and entered into 
EPI-INFO Version 3.5.1. And then statistical package 
SPSS software for windows, ver. 20 was used for all analy-
ses. Computed descriptive statistics were presented using 
texts and tables. Potential risk factors association with 
occurrence HBV infection was identified using bivariate 
and multivariate analysis. Multivariable logistic regres-
sion model was used to identify the relative importance 
of each predictor to the dependent variable by control-
ling for the effect of other variables. Exposure variables 
having statistically significant association with HBV 
infection after controlling the effect of other variables 
were considered as predictors of the outcome variables. 
Strength of association was measured using odds ratio 
(OR) with 95 % confidence interval (CI). Differences were 
considered significant if the p value was <0.05.
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